|Born||May 14, 1956
|Occupation||Founder and Managing Director, InCube Ventures (ICV)|
|Website||Profile of Mir at InCube Ventures|
Born and raised in India, the son of a doctor, Imran moved to New Jersey in 1973 to attend Rutgers University where he studied both electrical and biomedical engineering. He received his B.S. in electrical engineering and his M.S. in biomedical engineering and spent three years as a Research Specialist before deciding to leave and work on the first implantable cardioverter-defibrillator with Intec Systems, which was acquired by Eli Lilly, spun out to form Guidant, and acquired by Boston Scientific in 2006 for $27.5B
Imran is recognized for his history as a scientist, inventor, entrepreneur and investor of medical technology companies. He is the founder and Chairman of InCube Labs, LLC, a research laboratory and business incubator for medical and technology companies. Through InCube Labs, and prior to its establishment, he has founded numerous medical and high technology companies. Imran currently serves as a Director for a number of life science companies
Imran joined Intec Systems in 1980 and developed IP key to the development of the automatic implantable defibrillator, a device that has saved hundreds of thousands of lives, and has become a standard of care in cardiology. In 1992, Mr. Imran invented a cooled RF ablation catheter for the treatment of ventricular arrhythmias. This invention became the initial product of Cardiac Pathways, and is now widely used by cardiac electro-physiologists. In 1995, he developed a low-pressure balloon and aspirator system for use in catheter based interventions. Mr. Imran was the first to articulate the concept of embolic protection during high-risk interventions. Mr. Imran’s device became the primary innovation for Percusurge, which was acquired by Medtronic in December 2000. In the medical field Imran's interest is to develop medical devices that blur the distinction between organic and synthetic and advance patient treatment options.
Imran’s current research interests include tissue engineering, gastroenterology, nephrology, neurology, orthopedics, congestive heart failure and artificial organs.
Imran founded InCube Labs in 1995 after forming 8 venture backed medical device companies. Imran’s concept was that InCube would function as an applied research institute. Since the formation of InCube Labs, Imran has formed more than 12 additional companies.
Imran is an active angel investor and a limited partner in several venture funds. He is the Managing Director of InCube Ventures, a medical device venture fund.
InCube Ventures is an early stage life science venture capital fund. Imran co-founded InCube Ventures with Andrew Farquharson and Wayne Roe. The fund invests in both InCube Labs’ companies as well as external companies. The fund primarily invests in novel therapies that have the potential to dramatically improve patient care.
Awards and publications
2009 Rutgers Hall of Distinguished Alumni 
2005 Rutgers University Distinguished Engineer Award
Featured in EE Times - Nov 7th 2005 eeTimes
Featured in Stanford Medicine - Fall 2006 Stanford Medicine Magazine
Featured in Innovative Doctoring-Grossman, Jeffrey Innovative Doctoring
Featured in Medical Device and Diagnostics Magazine Incremental vs. Disruptive: A Parallel Entrepreneur on What Innovation Really Is
Medtronic Distinguished Lecturer at Johns Hopkins BioMedical Engineering Day – May 2007 Johns Hopkins BioMedical Engineering Day Brochure – May 2nd 2007
Keynote Speaker – Engineering in Medicine and Biology - UT Dallas - Nov 2007 UT Dallas Engineering in Medicine and Biology
- InCube Labs
- InCube Ventures
- eeTimes Magazine – Nov 7th 2005 – featuring Mir Imran
- Healthy Entrepreneurship in Medical Devices, podcast of Mir Imran speaking at Stanford
- Stanford Medicine, Fall 2006 – Device Guru’s article featuring Mir Imran
- UT Dallas, Engineering in Medicine and Biology – Nov 12th, 2007 – Keynote presentation by Mir Imran.
- Patents with Mir Imran listed as Inventor – USPTO.gov
- InCube Labs in the Daily Telegraph, UK